XOLAIR 150MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Product Information

Registration Status: Active

XOLAIR 150MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION is approved to be sold in Singapore with effective from 2006-07-07. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN13212P.

This product contains Omalizumab 150mg in the form of INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION. It is approved for SUBCUTANEOUS use.

This product is manufactured by Takeda Austria GmbH in SWITZERLAND,Novartis Pharma Stein AG in FRANCE, andDELPHARM DIJON - QUETIGNY in AUSTRIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Omalizumab

Description

A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.

Indication

For treatment of asthma caused by allergies

Mechanism of Action

Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.

Active Ingredient/Synonyms

Omalizumab | Omalizumab |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank